

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/574,337
Applicant : Seong Hwan Cho
Filed : May 9, 2006
TC/A.U. : 1614
Examiner : Amy A. Lewis

Docket No. : 1751-400
Customer No. : 06449
Confirmation No. : 8934

REQUEST FOR RECONSIDERATION

Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Reconsideration of the Office Action dated 31 December 2008 is requested in view of the following remarks.

The present invention is directed to a sustained-release formulation. According to claim 1, this sustained-release formulation comprises three elements. The first element is a sustained-release core which comprises an active ingredient, such as tamsulosin, and a polymer, such as hydroxypropylmethylcellulose, having erosion and swelling property in mammalian intestinal secretions. The second element is an enteric film coating layer coated on the sustained-release core. The third element is an active ingredient-containing film coating layer coated on the enteric film coating layer. The film coating layer comprises the active ingredient and a hydrophilic polymer, such as polyvinyl alcohol. According to claim 2, the sustained-release formulation may further comprise a fourth element which is an outer coating layer coated on the film coating layer. The outer coating layer comprises a film coating polymer, such as a copolymer of methacrylic acid and ethylacrylate. According to claim 8, the enteric film coating layer includes an enteric polymer, such as a copolymer of methacrylic acid and ethylacrylate.

The Examiner has rejected claims 1-16 under 35 U.S.C. § 102(b) as being anticipated by Shinoda et al. (US 2003/0147948). The Examiner contends that Shinoda et al. teaches an enteric